News

Pulmonary arterial hypertension (PAH) patients have given high marks to a new implanted,  programmable intravenous (IV) system that delivered Remodulin (treprostinil) to them with few complications, according to a clinical trial. The study, “Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System…

The INOpulse inhaled nitric oxide (iNO) delivery system improved lung-pressure measurements in pulmonary arterial hypertension (PAH) patients, according to its maker, Bellerophon Therapeutics. It presented the results at the 37th Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT) in San Diego April 5-8. The title of…

U.S. specialty biopharmas SteadyMed and United Therapeutics both issued media releases recently commenting on a ruling by the U.S. Patent and Trademark Office (USPTO) that declared invalid a United Therapeutics patent related to the drug treprostinil, a synthetic analogue of prostacyclin. Prostacyclin and its analogues are widely used in…

Due to regulatory delays, the U.S. launch of United Therapeutics‘s implanted pump system for the delivery of Remodulin (treprostinil) for patients with pulmonary arterial hypertension (PAH) will be postponed until 2018. “United Therapeutics’ commitment to bringing better therapies to patients transcends temporary delays or setbacks,” Martine Rothblatt, PhD,…

A significant proportion of patients with hyperthyroidism may have mild pulmonary hypertension (PH), according to the results of a recent study. Increased pulmonary vascular resistance may be the underlying cause of this association. The study, “Relationship Among Pulmonary Hypertension, Autoimmunity, Thyroid Hormones And Dyspnea In Patients With Hyperthyroidism,” was…

Pulmonary hypertension (PH) may be triggered by therapies used in chronic myeloid leukemia (CML) treatment, namely the drugs Gleevec (imatinib), Tasigna (nilotinib), or Sprycel (dasatinib), according to a recent study. The study, titled “Comparative Analysis Of Pulmonary Hypertension In Patients Treated With Imatinib, Nilotinib And Dasatinib,” was published in the…

An imaging technique called optical coherence tomography (OCT) can effectively determine abnormalities in the lung vasculature of pulmonary arterial hypertension (PAH) patients with systemic sclerosis (SSc), a study shows. The study, “Optical coherence tomography evaluation of pulmonary arterial vasculopathy in Systemic Sclerosis,” appeared in the journal Scientific…